Dosing vs Assessment Intervals With Faricimab and Aflibercept

This Viewpoint highlights the discrepancy between dosing and patient assessment schedules in clinical trials for 2 new intravitreal agents, faricimab, 6 mg, and aflibercept, 8 mg, to treat neovascular age-related macular degeneration.